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Nutrition During Trimodality Treatment in Stage III
Non-small Cell Lung Cancer
Not Only Important for Underweight Patients
Barbara S. van der Meij, MSc,*† Erik C. J. Phernambucq, MD,‡ Geert M. Fieten, MD,§
Egbert F. Smit, MD, PhD, Marinus A. Paul, MD, PhD,§ Paul A. M. van Leeuwen, MD, PhD,§
and J. Wolter A. Oosterhuis, MD, PhD§
Introduction: Trimodality treatment for stage III non-small cell
lung cancer (NSCLC), consisting of chemoradiotherapy followed by
surgery, is associated with treatment-related toxicity, malnutrition,
and postoperative complications. The aim of this retrospective study
was to investigate the predictive value of nutritional parameters on
postoperative morbidity, mortality, and survival.
Methods: Patients with stage III NSCLC undergoing concurrent
chemoradiotherapy followed by surgery in one center between 2003
and 2009 were included. Age, sex, forced expiratory volume in 1
second, body mass index, weight change, and surgical and patho-
logical factors were recorded and related to the occurrence of
postoperative complications/mortality, overall survival (OS), and
progression-free survival.
Results: Of 51 study patients, 17 (33%) had overweight (body mass
index  25) at start of treatment and 20 patients (39%) were
malnourished at hospital admission for surgery. Postoperative com-
plications occurred in 25 patients (49%), 6 had major complications,
and 2 died within 90 days after surgery, but no significant predictive
factors were found. Overall, weight loss 5% during induction
period was associated with shorter OS (p  0.03), but especially
overweight patients experiencing weight loss5% during induction
period (n  7) had shorter OS (hazard ratio 4.63, p  0.005;
log-rank p  0.04) and progression-free survival (hazard ratio 6.03,
p  0.007).
Conclusions: This study indicates that malnutrition especially in
overweight patients negatively influences survival outcomes of tri-
modality treatment for stage III NSCLC.
Key Words: NSCLC, Nutritional status, BMI, Concurrent chemo-
radiotherapy, Surgery.
(J Thorac Oncol. 2011;6: 1563–1568)
The debate for optimal treatment of stage III non-small celllung cancer (NSCLC) is mainly focused on the use of
different modalities, i.e., chemotherapy with surgery and/or
radiotherapy. However, survival still remains poor despite the
use of several chemotherapy regimens, implementation of con-
current radiotherapy, and extensive restaging before surgery. In
stage III NSCLC, the application of surgery after induction
treatment is controversial because no survival benefit has been
demonstrated in randomized clinical trials compared with che-
moradiotherapy (CRT) alone.1,2 In our practice, stage III
NSCLC patients without mediastinal lymph node involvement
and those with N2/N3 disease and proven mediastinal down-
staging after concurrent CRT are selected for surgery. In this
situation, consideration is given to the risk of local recurrence
and technical resectability of the primary tumor.
A minority of patients treated with upfront surgery for
NSCLC have a poor nutritional status, which has been shown
to be an independent risk factor for postoperative death and
reventilation after lung resection.3 In addition, malnutrition in
lung carcinoma is associated with advanced stage of disease
and is a reason for careful and extensive staging.4 Perioper-
ative nutritional support in malnourished surgical patients has
been shown to reduce the risk of postoperative complications
and death and is advocated by international guidelines.5 Apart
from a negative effect on surgical morbidity and mortality,
weight loss and catabolic state are associated with a negative
impact on long-term oncological outcomes in patients with
cancer, such as a reduced progression-free survival (PFS).6–9
The mechanisms for this phenomenon are poorly understood,
but immunologic processes may play an important role.10–13
However, it is unknown whether nutritional support can
ameliorate this phenomenon. Because cisplatin-based CRT is
associated with nausea, vomiting, diarrhea, anorexia, and
esophagitis, patients undergoing trimodality treatment may
become malnourished before surgery. Surgery after CRT is
associated with a higher morbidity and mortality, and weight
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loss and malnutrition which may occur during induction
treatment may be one of the causes.3,14 The importance of
nutritional factors as an independent risk factor for outcome
and long-term prognosis in patients operated after CRT is
however poorly studied.
The objective of this retrospective study was to inves-
tigate nutritional status and weight change during induction
CRT and to evaluate the influence of nutritional status vari-
ables on surgical morbidity/mortality and survival outcomes
in stage III NSCLC patients receiving trimodality treatment.
PATIENTS AND METHODS
Patient Selection
All consecutive patients with NSCLC who underwent
induction treatment with cisplatin-based chemotherapy and
concurrent thoracic radiotherapy followed by surgical resec-
tion from January 1, 2003, until December 31, 2009, in the
VU University Medical Center Amsterdam were included in
this study. NSCLC patients were selected for trimodality
treatment on basis of one or more of the following criteria:
1. Pathologically proven mediastinal lymph node involve-
ment (N2 or N3 disease), either by transbronchial fine
needle aspiration and/or esophageal ultrasonography
(endoscopic ultrasound-guided fine needle aspiration)
or mediastinoscopy.
2. Superior sulcus tumor (SST).
3. Consensus in the VU Medical Center Amsterdam mul-
tidisciplinary thoracic oncology meeting that the tumor
should be staged as cT4 on basis of a combination of
clinical signs (e.g., neurologic signs) and/or imaging
studies such as computed tomography scan or magnetic
resonance imaging (e.g., involvement of vertebra).
4. Eastern Cooperative Oncology Group performance sta-
tus 0 and 1.
5. Ability to tolerate cisplatin-based chemotherapy.
Trimodality Treatment
Two different induction schemes were used: (1) one
course of cisplatin and gemcitabine or pemetrexed followed
by two courses of cisplatin-etoposide (course cycle of 3
weeks) combined with radiotherapy (daily fractions of 2 Gy
to a total dose of 46–66 Gy); (2) six courses of weekly
cisplatin-docetaxel combined with radiotherapy (daily frac-
tions of 1.8 Gy to a total dose of 45 Gy). The latter scheme
was used in patients participating in a phase II study
(NVALT-6).15 After CRT, restaging was performed using
imaging studies and one or more of the abovementioned
invasive staging techniques. When no residual mediastinal
lymph node involvement was encountered and the primary
tumor was deemed resectable, patients underwent a thoracot-
omy approximately 5 weeks after the end of induction treat-
ment. If possible, a macroscopically complete resection of the
tumor was performed, preferably by lobectomy, combined
with an ipsilateral mediastinal lymphadenectomy. In right-
sided tumors, lymph node stations 2, 4, 7, 8, and 9 were
removed and in left-sided tumors stations 5, 6, 7, 8, and 9,
together with hilar and intralobar lymph nodes. The bronchial
stump was reinforced with a pedicled intercostal muscle flap
in all patients. SST were typically approached by a high
posterolateral incision (Shaw-Paulson), and all other resec-
tions were performed through a standard posterolateral tho-
racotomy.
Morbidity and Mortality
Anesthetic risk was determined for all patients using
the American Society of Anesthesiologists (ASA) score
(http://www.asahq.org/clinical/physicalstatus.htm). Postoper-
ative complications occurring within 90 days after surgery
were recorded and classified for type and severity. The type
of postoperative complications was subdivided into pulmo-
nary, cardiac, infectious, or miscellaneous. Severity was clas-
sified as (1) minor (non–life-threatening, no need for reintu-
bation, or admission to intensive care unit) or (2) major
(potentially life-threatening, need for reintubation, and/or
admission to intensive care unit).16 Patients having both
minor and major postoperative complications were classified
as having major complications, although the nature of the
minor complications was also recorded. A separate analysis
was made of infectious complications, because previous stud-
ies have shown that these are especially related to nutritional
status in abdominal and thoracic surgical patients.14,17 Infor-
mation on type of resection, length of postoperative hospital
stay, and 90-day postoperative mortality was recorded. Fol-
low-up data included last visit, first recurrence, and date/
cause of death. Overall survival (OS) and PFS were calcu-
lated from date of surgery to October 5, 2010, or date of last
radiological follow-up, respectively.
Nutritional Status
Nutritional status was assessed at start of first chemo-
therapy course (“baseline”) by recall of recent involuntary
weight loss and by measuring body mass index (BMI). BMI
was calculated as the ratio of body weight (kg)/height (m2).
Malnutrition was defined as 5% involuntary weight loss in
the previous month18 and/or underweight (BMI 18.5).
Overweight was classified as BMI 25, according to
the NIH classification of obesity (http://www.nhlbi.nih.gov/
health/public/heart/obesity/lose_wt/bmi_dis.htm).
During induction period, development of nutritional
status was investigated by follow-up of body weight at start
of week 6 after baseline (during CRT) and at hospital admis-
sion for surgery (surgery). Body weight, without shoes and
wearing light clothing, was measured on a compact digital
flat scale (SECA 708) to the nearest 0.1 kg at hospital
admissions for chemotherapy and surgery. The percentages
of weight change between preillness and baseline, baseline
and during CRT, and baseline and surgery were calculated.
Throughout treatment, nutritional status was monitored by
the medical staff, and the dietician was consulted whenever
necessary. Energy requirements were estimated using the
Harris Benedict 1984 equation including sex, age, body
weight, and height.19 To estimate total energy requirements,
130% of predicted resting energy expenditure was applied
(according to guidelines of the Dutch Malnutrition Steering
Group).20 Patients received enteral nutrition in case of mal-
nutrition and/or intake failure. Tube feeding was indicated in
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case of (expected) oral intake 75% of energy requirements
for more than 3 days, combined with the inability to increase
energy intake by oral food or sip feeds. Enteral nutrition was
supplied by oral nutritional supplements or tube feeding, the
latter via a nasogastric tube or a percutaneous endoscopic
gastrostomy (PEG) tube. Patients participating in the NVALT-6
phase II study received a PEG tube before the start of CRT.
Statistics
Independent variables (age, sex, stage of disease [N2/N3
versus T4 or SST], ASA score, CRT schedule, forced
expiratory volume in 1 second (FEV1), extent of lung
resection, postoperative pathological tumor node metasta-
sis (TNM) stage, BMI, and percentage of weight change)
were related to the occurrence of postoperative complica-
tions, 90-day postoperative mortality, OS, and PFS. Asso-
ciations between independent variables and postoperative
complications were investigated by logistic regression
analyses. To identify factors associated with OS and PFS,
Cox regression and Kaplan-Meier analyses were carried
out. Outcomes were adjusted for the following confound-
ing factors in the regression model (based on a 10%
change of OR after adding a single factor): age, sex, stage
of disease, chemotherapy scheme, pathological complete
remission, and/or extent of lung resection. p values less
than 0.05 were considered statistically significant.
RESULTS
Patient and Treatment Characteristics
Fifty-one patients were included (26 males), 26 patients
with involvement of N2/N3 lymph nodes and 41 patients with
a SST or T4 tumor. Median age at start of treatment was 57
years (range, 39–74 years). ASA score was I in 4 patients, II
in 30 patients, and III in 17 patients. Patient characteristics
are summarized in Table 1. Of 44 patients, results of pulmo-
nary function tests at diagnosis were available. Average
FEV1% of these patients was 87.5% (range, 33–126%).
Forty-two patients (82%) generally received one course of
cisplatin combined with gemcitabine or pemetrexed followed
by two courses of cisplatin-etoposide. Nine patients (18%)
received six weekly courses of cisplatin and docetaxel. Re-
sections consisted of pneumonectomy (n  4, 8%), bilobec-
tomy (n  3, 6%), lobectomy (n  39, 77%), and 5 patients
(10%) had a sublobar resection, because a more extended
resection was impossible for functional reasons. Macroscop-
ically complete resection was achieved in all patients. In three
patients (6%), the resection margins were microscopically
involved (R1 resection). These three cases were patients with
a SST in whom the lateral chest wall was microscopically
involved at the plane between the muscle fascia and the scapula.
Finally, pathological complete remission was achieved in 15
patients (29%).
Nutritional Status
At baseline and during CRT, 12 and 19 patients were
malnourished, respectively. Most patients (69%) maintained
weight between CRT and time of surgery, but on average, a
weight loss of 3.1% (range, 13.8 to 14.2) was observed for
the period between baseline and surgery. In addition, at time
of surgery, 20 patients were malnourished. Specifications on
nutritional status and weight change are shown in Table 1.
Forty-two patients (83%) received one or more dietetic con-
sultations. In 11 (22%) patients, a pretreatment PEG was
inserted. During induction period, 9 patients received naso-
gastric tube feeding and 42 (83%) patients used oral nutri-
tional supplements to increase their daily energy and nutrient
intake.
Postoperative Complications, Survival, and
Cause of Death
One or more postoperative complications occurred in
25 (49%) patients. Six patients had major complications and
two patients died within 90 days after surgery. The cause of
death in these two patients was acute respiratory distress
syndrome (ARDS) after pneumonectomy in one and sepsis in
TABLE 1. Patient Characteristics
Characteristic Result Range %
Sex (n)
Male 26 51
Female 25 49
Age at surgery (yr)
Median 57 39–74
65 (n) 35 69
65 (n) 16 31
Baselinea nutritional parameters
Mean body weight (kg) 70.3 46.8–98.1
Mean BMI (kg/m2) 24.0 18.0–40.3
BMI (n)
18.5 (underweight) 2 4
18–25 (normal weight) 32 63
25 (overweight) 17 33
Mean weight change (%)
Normal weight–baselinea 1.03 10.0 to 16.8
Baselinea–during CRT 2.7 15.4 to 8.5
Baselinea–admission for surgery 3.1 13.8 to 14.2
Malnourished patients (n)
At baselinea 12 24
During CRT 19 37
At surgery 20 39
ASA score (n)
I 4 8
II 30 59
III 17 33
Patients with complications (n)
Minor 19 37
Major 6 12
Number of complications
Pulmonary 14
Cardiac 5
Infectious 12
Miscellaneous 6
a Baseline is at start of first chemotherapy course.
BMI, body mass index; CRT, chemoradiotherapy; ASA, American Society of
Anesthesiologists.
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the other. Age, FEV1, sex, type of resection, and percentage
of weight change during induction period were not signifi-
cantly associated with postoperative complications or infec-
tious complications in univariate analysis (data not shown).
The mean length of postoperative hospital stay was 11.4 days
(range, 6–31 days). After a median follow-up of 36.9 months,
median OS had not been reached. The mean OS was 46.7
months and mean PFS 37.1 months. None of the preoperative
variables were significantly associated with OS or PFS in
univariate analysis (Table 2). However, pneumonectomy was
associated with shorter PFS (HR 4.91, p  0.02) and com-
plete pathological remission with a longer PFS (HR 0.26, p
0.03). Weight loss 5% from baseline until surgery was
associated with shorter OS (HR 2.80, p  0.03). Especially
overweight patients who experienced a weight loss of 5%
(n  7) tended to have a shorter OS (adjusted HR 4.63, p 
0.005) and PFS (adjusted HR 6.03, p  0.007). In addition,
Figure 1 shows the Kaplan-Meier OS curve for last-men-
tioned group compared with the other study patients (log-rank
p 0.04). At the date of survival analysis, in total 22 patients
(43%) have died of which 10 were noncancer-related death.
Respiratory failure was the cause of death in seven of latter
patients. Finally, the overweight patients who experienced a
weight loss of 5% died of cancer (n  2) or respiratory
failure (n 3), but only one of them died within 90 days after
surgery (ARDS).
DISCUSSION
In this study, a well-defined group of 51 stage III
NSCLC patients underwent trimodality treatment, consisting
of concurrent CRT followed by surgery. The nutritional
status of patients was not only determined at baseline but also
monitored continuously during CRT and thereafter until sur-
gery. A high number of postoperative complications were
observed, which is in line with other series of lung resections
after induction CRT.1,2,21 However, most complications were
minor, and postoperative mortality was lower than in other
studies.1,21 None of the preoperative risk factors, including
nutritional status, were predictive for postoperative compli-
cations. In general, obese patients are thought to be at higher
risk for postoperative complications due to more difficulty in
mobilization, impaired wound healing, and atelectasis.22 How-
ever, several studies found that only morbidly obese patients
have a higher risk of major complications or mortality after
general surgical procedures and major intra-abdominal onco-
logical resections. A low risk was observed for moderately
obese patients.17 BMI has not been found to be a risk factor
FIGURE 1. Overall survival. Kaplan Meier overall survival
curve of overweight patients (BMI 25) experiencing 5%
weight loss during induction period (n  7) compared with
other study patients (n  44) (log-rank p  0.04).
TABLE 2. Associations between Independent Variables and Overall/Progression-Free Survival
Overall Survival Progression-Free Survival
HR 95% CI p HR 95% CI p
Sex (male vs. female) 1.91 0.73–4.97 0.19 1.81 0.75–4.40 0.19
Age (65 vs. 65 yr) 1.16 0.46–2.94 0.75 1.21 0.51–2.90 0.66
Stage of disease (SST/T4 vs. N2/N3) 0.81 0.30–2.23 0.69 0.75 0.29–1.93 0.55
BMI at baseline (25 vs 25 kg/m2) 1.75 0.70–4.38 0.23 1.41 0.59–3.36 0.45
FEV1 (%) 1.00 0.98–1.03 0.97 1.00 0.97–1.02 0.66
Chemotherapy scheme (cisplatin-docetaxel vs other) 1.21 0.46–3.22 0.70 0.67 0.24–1.90 0.45
ASA score (III vs. I/II) 1.17 0.49–2.80 0.72 0.64 0.26–1.53 0.31
Extent of lung resection (pneumonectomy vs. other) 2.32 0.55–9.73 0.25 4.91 1.40–17.18 0.02a
Completeness of resection (R0 vs. R1) 1.83 0.51–6.57 0.35 2.28 0.59–8.73 0.233
Complete pathological remission (yes vs. no) 0.32 0.10–1.08 0.07 0.26 0.08–0.88 0.03a
Weight loss 5% between baseline and surgery 2.80 1.10–7.13 0.03a 1.77 0.75–4.16 0.19
BMI 25 and 5% weight loss between baseline and surgery 4.63 1.58–13.56 0.005a 6.03 1.65–22.11 0.007a
Cox regression for progression-free and overall survival, adjusted for confounding factors.
a p  0.05.
HR, hazard ratio; CI, confidence interval; SST, superior sulcus tumor; BMI, body mass index; FEV1, forced expiratory volume in 1 s; ASA, American Society of
Anesthesiologists; R0, complete resection; R1, microscopic residual disease.
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for complications of mortality in patients operated for esoph-
ageal cancer or lung cancer.23–25
Several studies have indicated a higher risk for postoper-
ative complications and death in malnourished patients.3,14,17,26
Although all patients in our study received intensive nutritional
support during induction treatment, the percentage of malnour-
ished patients at time of surgery was 39% compared with 24%
at baseline, indicative of the toxicity of induction treatment with
CRT.Malnutrition measured at different phases of the treatment,
however, was not associated with outcome in terms of postop-
erative complications or mortality. This is in line with previous
studies showing that nutritional support in malnourished surgical
patients, as was given in our study group, reduces postoperative
morbidity and mortality.5,14 Our study shows that in general,
surgery can be performed safely after CRT despite worsening of
the nutritional status during induction treatment, provided that
patients receive adequate nutritional support throughout the
treatment period.
Next to the observation that weight loss 5% during
induction period predicted for shorter OS, a remarkable
finding was that especially the combination of overweight
and weight loss 5% during induction treatment predicted
for both poor OS and PFS, suggesting that the development
of malnutrition during induction CRT in overweight patients
impairs not only surgical outcome but also long-term onco-
logical outcome. Therefore, the nutritional status of (over-
weight) patients treated with CRT and surgery for NSCLC
should be monitored throughout the entire treatment period
and not only at the start of the treatment.
Obesity leads to central fat deposition, disordered en-
ergy use by cell mitochondria, especially in muscle and liver,
and malfunctioning immune, coagulation, endothelial, and
other systems.27 Patients with a high BMI, experiencing
undesired weight loss, might also develop malnutrition. How-
ever, little is known about the consequences of malnutrition
on body composition in obesity. Probably the relatively low
fat-free mass in obese patients might result in altered meta-
bolic pathways, which might influence the response to sur-
gery after CRT and the hosts’ immune response to the
malignant tumor. In daily practice, recognition of malnutri-
tion in patients with overweight, who do not appear to be
malnourished at first sight, rarely takes place. Therefore,
recognition by regular weighing during the induction period
and treatment of malnutrition in patients with overweight or
obesity may be beneficial.
The main limitation of this study is a small, selected
study population. The toxicity of trimodality treatment makes
careful patient selection imperative. As a result, statistical
power is low and the importance of other risk factors might
have been overlooked.
In conclusion, this study, focusing on the significance
of nutritional status in stage III NSCLC patients undergoing
trimodality treatment did not identify predicting factors for
general postoperative complications. Despite nutritional sup-
port throughout the treatment period, especially overweight
patients (BMI 25) who suffered from weight loss 5%
during induction treatment had a significantly shorter OS and
PFS. These findings indicate that (mal)nutrition during ag-
gressive trimodality treatment is an important factor with
potentially negative impact on outcomes in stage III NSCLC,
not only in underweight patients but also in those with
overweight at initial diagnosis.
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